114 related articles for article (PubMed ID: 27349366)
1. Bladder cancer: Cisplatin response is modulated by AR activity.
Fenner A
Nat Rev Urol; 2016 Aug; 13(8):437. PubMed ID: 27349366
[No Abstract] [Full Text] [Related]
2. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
3. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
5. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.
Shiota M; Tsunoda T; Song Y; Yokomizo A; Tada Y; Oda Y; Naito S
BJU Int; 2011 Apr; 107(7):1148-53. PubMed ID: 20726978
[TBL] [Abstract][Full Text] [Related]
6. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line.
Miyake H; Hara I; Gohji K; Yoshimura K; Arakawa S; Kamidono S
Cancer Lett; 1998 Jan; 123(2):121-6. PubMed ID: 9489477
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.
Teramoto Y; Jiang G; Goto T; Mizushima T; Nagata Y; Netto GJ; Miyamoto H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576193
[TBL] [Abstract][Full Text] [Related]
8. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.
Zuiverloon TC; Theodorescu D
Pharmacogenomics; 2017 Aug; 18(12):1167-1178. PubMed ID: 28745580
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
12. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of the androgen receptor in bladder cancer.
Lombard AP; Mudryj M
Endocr Relat Cancer; 2015 Oct; 22(5):R265-77. PubMed ID: 26229034
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line.
Chen L; Chang WC; Hung YC; Chang YY; Bao BY; Huang HC; Chung WM; Shyr CR; Ma WL
Reprod Sci; 2014 Mar; 21(3):386-94. PubMed ID: 23962788
[TBL] [Abstract][Full Text] [Related]
15. New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
McKeage MJ
Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
Sonpavde G; Galsky MD; Latini D; Chen GJ
Clin Genitourin Cancer; 2014 Apr; 12(2):71-3. PubMed ID: 24355418
[No Abstract] [Full Text] [Related]
18. Mechanism of cisplatin resistance in human urothelial carcinoma cells.
Yu HM; Wang TC
Food Chem Toxicol; 2012 May; 50(5):1226-37. PubMed ID: 22326969
[TBL] [Abstract][Full Text] [Related]
19. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor activation: a prospective therapeutic target for bladder cancer?
Mizushima T; Tirador KA; Miyamoto H
Expert Opin Ther Targets; 2017 Mar; 21(3):249-257. PubMed ID: 28064545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
